The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)

Cima, Katharina; Twiss, James; Speich, Rudolf; McKenna, Stephen P.; Grünig, Ekkehard; Kähler, Christian M.; Ehlken, Nicola; Treder, Ursula; Crawford, S.R.; Huber, Lars C; Ulrich, Silvia

doi:10.1186/1477-7525-10-110

Cited by 37 publications

(32 citation statements)

References 29 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The MLHF questionnaire consists of a general score (range 0-105), a physical subscore (range 0-40) and an emotional subscore (range 0-25), with higher scores reflecting poorer quality of life. In addition, we used the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) questionnaire specifically designed for PH, consisting of scales for symptoms (25 items), activity limitation (15 items) and quality of life (25 items), with a maximum score of 65 and likewise higher scores reflecting worse HRQoL [22,23,24]. …”

Section: Methodsmentioning

confidence: 99%

Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background: Pulmonary hypertension (PH) leads to reduced health-related quality of life (HRQoL). Objective: To investigate the prevalence and course of anxiety and depression and their association with HRQoL, disease severity and survival in PH. Methods: 131 PH patients (91 pulmonary arterial, 30 chronic thromboembolic, 10 due to lung disease; 84 female, 47 male) had repeated assessments with the Hospital Anxiety and Depression Scale (HADS), HRQoL, six-minute walk distance and WHO functional class during a mean course of 16 ± 12 months. Results: Among the 49 incident and 82 prevalent PH patients, the HADS score was positive in 53%/21% (depression), 51%/24% (anxiety) and 63%/26% (total score) (all p < 0.05). The HADS score was improved at the second assessment in incident patients. The HADS score correlated with HRQoL at all consecutive assessments and with functional class until the third assessment, but not with baseline hemodynamics, age or gender. Conclusion: Mood disorders remain underdiagnosed in PH. The higher prevalence of anxiety/depression in incident versus prevalent patients and the improvement over time may indicate an amelioration of mood disorders after PH diagnosis and treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Demographics, medical history, New York Heart Association (NYHA) functional class and HRQoL - Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) [3,17] - were assessed. The 6-min walk distance (6MWD) test was performed according to guidelines [18].…”

Section: Methodsmentioning

confidence: 99%

Disease-Targeted Treatment Improves Cognitive Function in Patients with Precapillary Pulmonary Hypertension

Somaini¹,

Stamm²,

Müller-Mottet³

et al. 2015

Respiration

Self Cite

View full text Add to dashboard Cite

Background: Patients with pulmonary hypertension (PH) may suffer from cognitive deficits that potentially relate to reduced oxygen delivery and cerebral tissue oxygenation (CTO). Objective: To evaluate the hypothesis that cognitive function improves with therapy, along with improved CTO. Methods: Twenty incident patients with arterial or chronic thromboembolic PH had CTO monitoring by near-infrared spectroscopy during diagnostic right heart catheterization. Cognitive tests [Trail Making Tests (TMTs), Victoria Stroop tests and the Five-Point Test (5PT)], the 6-min walk distance (6MWD) test, New York Heart Association (NYHA) class and health-related quality of life (HRQoL) were assessed and repeated after 3 months of disease-targeted medication. Results: At baseline, 45% of PH patients had cognitive deficits. At 3 months, the patients had improved on the TMT A and the Stroop 2 test [37 s (27; 55) versus 30 s (24; 42), p < 0.05, and 18 s (16; 22) versus 16 s (15; 20), p < 0.01], whereas CTO remained unchanged. Arterial oxygen saturation, NYHA class, 6MWD and HRQoL had also improved. Baseline CTO was the strongest predictor of cognitive function, even in multivariate analysis including age, 6MWD and HRQoL. Improvements in cognitive function were not associated with changes in CTO. Conclusions: In patients with PH, 3 months of disease-targeted medication resulted in better cognitive function. Although CTO was the strongest predictor of cognitive function at baseline, it did not change during target therapy. The results of this pilot study should be confirmed in an adequately powered controlled trial.

show abstract

“…Baseline assessment and follow-up after 6 months of therapy included a thorough clinical examination, assessment of the NYHA functional class and 6MWD according to international guidelines [14], a full invasive hemodynamic evaluation, and exploration of the health-related quality of life using the German version of the CAMPHOR questionnaire [15]. This score ranges from 0 (best) to 80 (worst).…”

Section: Methodsmentioning

confidence: 99%

Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension

et al. 2015

Self Cite

View full text Add to dashboard Cite

Background: Antiproliferative strategies have emerged as a potential therapeutic option for pulmonary arterial hypertension (PAH). Objective: To evaluate the long-term efficacy and safety of imatinib. Methods: This is an observational study of 15 patients with idiopathic PAH (n = 13) or PAH associated with connective tissue disease (n = 2) treated off-label with imatinib 400 mg daily. Pulmonary hypertension-specific therapy was established in all patients (triple therapy in 10, dual therapy in 3, and monotherapy in 2 patients). Results: After 6 months, improvement in hemodynamics (p < 0.01), functional class (p = 0.035), and quality of life (p = 0.005) was observed. After a median follow-up of 37 months, there was a sustained improvement in functional class (p = 0.032), quality of life (p = 0.019), and echocardiographic parameters of right ventricular function (p < 0.05). Three patients (20%) presented with completely normal echocardiography, absent tricuspid regurgitation, and normal pro-brain natriuretic peptide levels, indicative of ‘hemodynamic remission'. Of note, however, only 1 case was assessed by invasive hemodynamics. The overall 1- and 3-year survival was 100 and 90%, respectively. Two patients experienced a subdural hematoma (SDH), which in both cases resolved without sequelae. After careful consultation of the potential risks and benefits, all patients as well as a safety cohort of 9 subsequent cases decided to continue the imatinib therapy. After adjusting the target international normalized ratio (INR) to around 2.0, no further cases of SDH occurred during 50 patient-years. Conclusions: Long-term treatment with imatinib may improve the functional class and quality of life. Single cases might even attain hemodynamic remission. The occurrence of 5% SDH per patient-years is concerning. However, adjusting the INR to around 2.0 might obviate this complication.

show abstract

The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)

Cited by 37 publications

References 29 publications

Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy

Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy

Disease-Targeted Treatment Improves Cognitive Function in Patients with Precapillary Pulmonary Hypertension

Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension

Contact Info

Product

Resources

About